Imagine discovering that a rare genetic disorder isn't quite what it seems – that patients mimicking its symptoms don't carry the expected gene mutation. This revelation isn't just intriguing; it challenges how we approach diagnosis and treatment in endocrinology. But here's where it gets controversial: are these 'phenocopies' truly distinct, or might they hint at undiscovered genetic links? Dive in as we explore a groundbreaking study that uncovers the nuances of MEN1-like conditions, shedding light on why some patients defy the genetic blueprint.
The Clinical Puzzle of MEN1 Phenocopies: Key Findings from a Nationwide Multicenter Retrospective Analysis
- Open Access
- 12-11-2025
- Neuroendocrine Tumor (https://www.springermedicine.com/topic/Neuroendocrine%20Tumor)
- Original Article
Authors
Rosaria M. Ruggeri
Elio Benevento
Iderina Hasballa
Erika Maria Grossrubatscher
Roberta Modica
Manuela Albertelli
Bianca Golisano
Vito Guarnieri
Flavia Pugliese
Valentina Guarnotta
Simona Jaafar
Andrea Lania
Antonio Prinzi
Isabella Zanata
Maria Chiara Zatelli
Annamaria Colao
Antongiulio Faggiano
on behalf of NIKE Group
Published in
Journal of Endocrinological Investigation (https://www.springermedicine.com/journal-of-endocrinological-investigation/25675452)
Abstract
Multiple endocrine neoplasia type 1, often abbreviated as MEN1, is a hereditary condition passed down in an autosomal dominant fashion, triggered by alterations in the MEN1 gene. It commonly manifests through primary hyperparathyroidism (PHPT) – a disorder where the parathyroid glands produce too much parathyroid hormone, leading to high calcium levels – along with pancreatic neuroendocrine tumors (PanNETs), which are growths in the pancreas that can secrete hormones, and sometimes pituitary neuroendocrine tumors (PitNETs), affecting the pituitary gland that regulates various bodily functions. To help beginners grasp this, think of MEN1 as a genetic glitch that sets off a chain reaction in multiple endocrine glands, potentially causing a trio of serious health issues like overactive glands, pancreatic tumors, and pituitary problems.
Yet, surprisingly, about 10% to 30% of individuals who exhibit these classic MEN1 symptoms don't show any detectable MEN1 gene mutations. These cases are termed 'phenocopies' – essentially, look-alikes that imitate the disease's features without the genetic root cause. This large-scale retrospective study, spanning 10 specialized centers in Italy, set out to delve into the primary characteristics of these phenocopies. Over a span of five years, researchers assessed 240 patients suspected of having MEN1. Of these, 175 (with an average age of 43.2 years and a standard deviation of 19.7; 101 were women) had confirmed MEN1 through genetic testing. Meanwhile, 65 patients (making up 27%; average age 59.9 ± 11.6; 44 women) were classified as phenocopies. Among them, 46 (or 70.7%) also tested negative for mutations in the CDKN1B gene, which is linked to a rarer condition called MEN4, thus underscoring how uncommon MEN4 truly is.
And this is the part most people miss: phenocopies are often identified 10 to 20 years later than true MEN1 cases (with a statistically significant difference, p < 0.0001). While PHPT remained the most prevalent symptom in both groups (affecting 80% of phenocopies and 81% of MEN1 patients), the combinations of tumors varied dramatically (p < 0.001). In the MEN1 group, 41% displayed the full classic trio of PHPT, PanNETs, and PitNETs. In stark contrast, only 1% of phenocopies showed this complete set. Instead, MEN1 patients more frequently had PHPT paired with neuroendocrine tumors (NETs) in general (32%), but phenocopies were far more likely to have PHPT alongside PitNETs (54%), which aligns more closely with patterns seen in non-hereditary, sporadic tumors that arise randomly without a genetic predisposition.
Intriguingly, 11% of phenocopies had a close family member – like a parent, sibling, or child – who had been diagnosed with MEN1-associated conditions, suggesting possible indirect genetic influences or shared environmental factors. Additionally, 51% reported either their own history of cancer or a family background of malignancies. In wrapping up, MEN1 phenocopies are far from rare and pose a significant diagnostic dilemma for clinicians. Because of their unique presentation and familial connections, experts recommend broader genetic testing panels for these patients, coupled with ongoing monitoring for MEN1-related ailments to catch any issues early.
But here's where it gets controversial: should we expand genetic screening to everyone with MEN1-like symptoms, even if costs rise and false positives complicate matters? And this is the part most people miss: if phenocopies represent hidden genetic variants we haven't discovered yet, could they be the tip of an iceberg of undiagnosed hereditary syndromes? What do you think – are phenocopies just mimics, or might they reveal flaws in our current genetic testing methods? Share your thoughts in the comments; I'd love to hear if you agree or disagree!
- Metadata
- Literature
Title
The Clinical Puzzle of MEN1 Phenocopies: Key Findings from a Nationwide Multicenter Retrospective Analysis
Authors
Rosaria M. Ruggeri
Elio Benevento
Iderina Hasballa
Erika Maria Grossrubatscher
Roberta Modica
Manuela Albertelli
Bianca Golisano
Vito Guarnieri
Flavia Pugliese
Valentina Guarnotta
Simona Jaafar
Andrea Lania
Antonio Prinzi
Isabella Zanata
Maria Chiara Zatelli
Annamaria Colao
Antongiulio Faggiano
on behalf of NIKE Group
Publication date
12-11-2025
This content is only visible if you are logged in and have the appropriate permissions.
Keynote webinar | Spotlight on progress in colorectal cancer (https://www.springermedicine.com/webinar-progress-in-colorectal-cancer/51577744)
- Live
- Webinar | 11-12-2025 | 18:00 (CET)
CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.
Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)
Prof. Antoni Castells
Prof. Edward Giovannucci
Join the webinar (https://www.springermedicine.com/webinar-progress-in-colorectal-cancer/51577744)
2025 ESMO Congress hub (https://www.springermedicine.com/esmo-2025/51417618)
- Oncology (https://www.springermedicine.com/topic/Oncology)
- Congress News
Unlock your free and exclusive access to expert interviews, news, and more from the annual congress of the European Society for Medical Oncology.
Read more (https://www.springermedicine.com/esmo-2025/51417618)
Image Credits
Colon cancer illustration/© (M) KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images, Cancer cell screening and treatment concept/© artacet / iStock / Getty Images Plus, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images
